Analyst Ratings For Glaukos
Portfolio Pulse from Benzinga Insights
Analyst ratings for Glaukos (NYSE:GKOS) have shown a mix of perspectives, with recent updates indicating a generally positive outlook. The average 12-month price target for GKOS has been raised to $93.43, up 8.64% from the previous $86.00. Analysts from firms like Needham, Truist Securities, Piper Sandler, JP Morgan, and Morgan Stanley have maintained or raised their ratings and price targets, reflecting optimism about the company's future performance. Glaukos, an ophthalmic medical technology company, has shown a revenue growth rate of 9.51% as of September 30, 2023, but struggles with profitability and financial efficiency, as indicated by its below-industry-average net margin, ROE, and ROA.
February 16, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have a generally positive outlook on Glaukos, with an increased average 12-month price target of $93.43. Despite this optimism, the company faces challenges in profitability and financial efficiency.
The positive adjustments in analyst ratings and price targets for Glaukos suggest a bullish sentiment towards the company's stock in the short term. However, the company's below-average performance in profitability and financial efficiency metrics such as net margin, ROE, and ROA, alongside a high debt-to-equity ratio, may temper investor enthusiasm. The overall positive analyst outlook, combined with the company's revenue growth, suggests a potential short-term upward movement in stock price, but investors should remain cautious of the underlying financial challenges.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100